Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a phase Ⅲ multicenter, open-label, follow-up study, to assess the safety and efficacy
of certolizumab pegol (CZP) as additional medication to methotrexate (MTX), in patients with
active rheumatoid arthritis (RA) who participated in Study (Protocol) # 101-KOA-0801i.